All News

tomatoes olive oil and whole grains

Best of 2024: Eating for Rheumatoid Arthritis

d Kathryn H. Dao, M.D.

The majority of practicing rheumatologists at RheumNow Live 2024 were unaware of the new ACR guidelines issued in 2022 regarding dietary and lifestyle recommendations for patients with Rheumatoid Arthritis. Dr. Monica Guma reviewed these guidelines during her lecture on the impact of diet on disease activity and therapeutic response.  

Read Article
vitamin-d-3091385_640.jpg

Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women

d Jack Cush, MD

A follow-up analysis of a randomized clinical trial found that the use of calcium and vitamin D supplements among postmenopausal women was associated with decreased risk for cancer mortality, but increased risk for cardiovascular disease mortality. The analysis is published in Annals of Internal Medicine.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus

d Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
steroid prednisone lab

Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency

d Jack Cush, MD

Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility.

Read Article
kidneys

Best of 2024: Efficacy of Biologics in Patients with Chronic Kidney Disease

d Jack Cush, MD

A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis patients with chronic kidney disease, shows the 3 year survival to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.

Read Article
ild.jpg

Best of 2024: 13 Risk Factors for RA-associated Interstitial Lung Disease

d Jack Cush, MD

Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.

Read Article
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2

Links:

Dr. John Cush RheumNow ( View Tweet)
"If you want an argument, put two rheumatologists in a room and ask them about steroid tapers. Add a third and you'll have a fight" -P. Merkel at UPA plenary session #ACR24 @RheumNow

Dr. John Cush RheumNow ( View Tweet)

Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years. Usually, seroneg RA means seroneg RA! #ACR24 @MyasoedovaElena ABST0458 @RheumNow… https://t.co/OD78mbDyNu https://t.co/vHgqX9IQOs
Dr. John Cush RheumNow ( View Tweet)
Myths by Daniel Clauw Small fiber neuropathy - misnomer, non-specific, not worth getting a skin biopsy Fibromyalgia is not autoimmune - it is nociplastic pain and treated differently #ACR24 Review Course @RheumNow https://t.co/7SGKMTC3HY https://t.co/0718sGsass

Links:

Dr. John Cush RheumNow ( View Tweet)
Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/f7OwxAggaf… https://t.co/PUuwo0MLso https://t.co/JBzokT9icx

Links:

Dr. John Cush RheumNow ( View Tweet)
Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow… https://t.co/aR75hJQ6YK https://t.co/ptDYCsOpXN
Dr. John Cush RheumNow ( View Tweet)
ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/7Lo0DgHtXT) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow… https://t.co/lZ1TJxTqhs https://t.co/itx0TCFFjl

Links:

Dr. John Cush RheumNow ( View Tweet)
Great table re:side effects of even low dose steroids in RA Likely generalizes to other diseases ie PMR, SLE P in prednisone stands for poison! #ACR24 @RheumNow https://t.co/2bFy6dwl96 https://t.co/YDtjSX054I

Links:

Dr. John Cush RheumNow ( View Tweet)
TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/F9DOBLrjVq https://t.co/BtphAuEopA

Links:

Dr. John Cush RheumNow ( View Tweet)
54K Peptic Ulcers Annually (12.13.2024) https://t.co/18FiQx1YQA https://t.co/32UZi9XafS

Links:

Dr. John Cush RheumNow ( View Tweet)
Improvements in Pain and Fatigue in Bimekizumab Dr. Philip Mease discusses abstract 2368, presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/ON09z9yTuJ https://t.co/650TUdHwYm

Links:

Dr. John Cush RheumNow ( View Tweet)
Vaccine Responses:The DMARD Counts Dr. David Liew reviews abstracts 0247, 0248, 1988, 1009, reporting from Melbourne, Australia for the 2024 ACR Convergence meeting. https://t.co/0qDGRkT64B https://t.co/dO9EvhD1NE

Links:

Dr. John Cush RheumNow ( View Tweet)
How do you manage skin in Sscl? -RNA pol III + high risk for skin progression. -Limited+ low risk + stable Sscl no need for immunesuppresors. -Look for EF in pts with generalized morphea. -Ttnt of skin depending on other organ involvements. -If no Raynaud’s/hands spared think of… https://t.co/DZzhShKzS8 https://t.co/J9Qg1Lk2Wl
Dr. John Cush RheumNow ( View Tweet)
#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/g3egOpCYNr https://t.co/KMiOEP7pSg
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×